Pyxis Oncology surges 16% as MICVO Phase I shows 39% response rate

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Pyxis Oncology (PYXS.US) surged more than 16% during regular trading to $1.95.

The biotechnology industry index rose 1.5% over the same period.

The company reported updated Phase I trial data for MICVO in 33 patients with second-line or later recurrent or metastatic head and neck squamous cell carcinoma, showing a confirmed objective response rate of 39%, a disease control rate of 94%, median progression-free survival of 6.7 months, median duration of response of 9.2 months and a 12-month overall survival probability of 79%. Pyxis said the data support its planned global Phase III HeadlinerSM clinical trial scheduled to begin in mid-2027.

Separately, Pyxis narrowed its third-quarter net loss as expenses declined. Previously reported data for MICVO monotherapy in advanced head and neck cancer showed a confirmed response rate of 36% and median progression-free survival of 6.2 months.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.